A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
Launched by TAMPERE UNIVERSITY HOSPITAL · Jan 9, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the issue of retained needle fragments in people who use intravenous drugs (IVD). When someone injects drugs, small pieces of the needle can sometimes break off and stay in the body, which can lead to pain, infections, and even serious complications like damage to organs. The researchers want to find out how common this problem is and what factors might increase the risk of having these needle fragments.
To participate in the study, you need to have a history of using intravenous drugs and be currently receiving treatment for drug abuse at a local health service. If you join, you will fill out a questionnaire and have X-ray imaging done to check for any retained needle fragments. This study is looking for participants of any gender who are between the ages of 18 and 74. It’s important to know that if you are pregnant or do not meet the inclusion criteria, you won't be able to participate. By taking part in this research, you will help provide valuable information that could benefit others in similar situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • History of intravenous drug use
- • Current treatment of the drug abuse problem at a local low-threshold drug abuse service unit or primary health care centre.
- • Adherence to fill in the questionnaire
- • Participation to X-ray imaging of injection sites
- Exclusion Criteria:
- • No history of intravenous drug use
- • Does not adhere to fill in the questionnaire or refuses X-ray imaging
- • Pregnancy
- • Underage (18 years old)
About Tampere University Hospital
Tampere University Hospital (TAYS) is a leading academic medical center in Finland, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, TAYS integrates cutting-edge medical practices with rigorous scientific investigation, focusing on improving patient outcomes and enhancing treatment modalities across various specialties. The hospital collaborates with a network of researchers, healthcare professionals, and academic institutions to foster a multidisciplinary approach to medical research, ensuring that findings are translated into real-world applications for the benefit of patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampere, , Finland
Patients applied
Trial Officials
Otso Arponen, MD-PhD
Study Chair
Pirkanmaa Hospital District (PSHP)
Olli PO Nevalainen, MD-PhD
Study Chair
City of Tampere; Tampere University; Pirkanmaa Hospital District (PSHP).
Irina Rinta-Kiikka, MD-PhD
Study Chair
Tampere University Hospital
Heidi Laukkala, MD
Study Chair
City of Tampere, Tampere University
Markku Sumanen, MD-PhD
Principal Investigator
Tampere University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials